Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease
APM-Project
2 other identifiers
observational
500
1 country
21
Brief Summary
The aim of this non-investigational study is to determine the symptoms and disease burden at the time point of diagnosis and in the further course of an incurable cancer disease. The needs and preferences of patients suffering from cancer (ovarian carcinoma, breast cancer, malignant melanoma, lung cancer, stomach cancer, oesophageal cancer, pancreatic cancer, cancer of the hepatobiliary system, colorectal cancer, head and neck cancer) are examined by various validated questionnaires. The data obtained by these questionnaires are collected together with information obtained by the treating physicians at four time points during the study: t0 - patient´s enrollment, at the moment of diagnosis and before the start of tumor therapy, respectively; T1 - 3 months after patient´s enrollment; T2 - 6 months after patient´s enrollment; T3 - 12 months after patient´s enrollment. This highly innovative project offers the chance to identify medical services deficits and risk circumstances for the burden of treatments in an oncology-palliative setting and to optimize the quality of patient care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2014
Longer than P75 for all trials
21 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 14, 2016
CompletedFirst Posted
Study publicly available on registry
April 26, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2019
CompletedMarch 7, 2019
March 1, 2019
5.1 years
April 14, 2016
March 6, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change from Baseline Patient´s answers regarding symptom burden at 12 months
12 months after enrollment
Secondary Outcomes (5)
Change from Baseline physician´s report at 12 months
12 months after enrollment
Change from Baseline Patient´s answers regarding symptom burden at 6 months
6 months after enrollment
Change from Baseline physician´s report at 6 months
6 months after enrollment
Change from Baseline Patient´s answers regarding symptom burden at 3 months
3 months after enrollment
Change from Baseline physician´s report at 3 months
3 months after enrollment
Study Arms (10)
lung cancer
validated questionnaires
malignant melanoma
validated questionnaires
cancer of the hepatobiliary system
validated questionnaires
head and neck cancer
validated questionnaires
breast cancer
validated questionnaires
ovarian carcinoma
validated questionnaires
pancreatic cancer
validated questionnaires
stomach cancer
validated questionnaires
oesophageal cancer
validated questionnaires
colorectal cancer
validated questionnaires
Interventions
Eligibility Criteria
patients with newly diagnosed incurable cancer disease before start of any tumor therapy
You may qualify if:
- Incurable cancer disease: ovarian carcinoma, breast cancer, malignant melanoma, lung cancer, stomach cancer, oesophageal cancer, pancreatic cancer, cancer of the hepatobiliary system, colorectal cancer, head and neck cancer
- signed and dated Inform Consent Form
- Age ≥ 18 years
You may not qualify if:
- Patient is not able to understand and to answer questions
- Patient is in a critical health situation and is directly threatened due to cancer disease or the resulting complications
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (21)
UCCL, University of Leipzig
Leipzig, Saxony, 04103, Germany
Municipal Hospital Braunschweig
Braunschweig, Germany
Internal medicine practice
Burgwedel, Germany
Municipal Hospital Essen-Mitte
Essen, Germany
University of Essen
Essen, Germany
University of Göttingen
Göttingen, Germany
University of Hamburg-Eppendorf
Hamburg, Germany
Medical University Hanover
Hanover, Germany
Clinic for Thoraric Diseases (Thoraxklinik)
Heidelberg, Germany
Municipal Hospital Karlsruhe
Karlsruhe, Germany
University of Leipzig, ENT
Leipzig, Germany
Hospital Leverkusen
Leverkusen, Germany
Municipal Hospital Magdeburg
Magdeburg, Germany
University of Mainz
Mainz, Germany
Maria Hilf Clinic
Mönchengladbach, Germany
Radiotherapy practice
Recklinghausen, Germany
University of Regensburg
Regensburg, Germany
Hospital Südstadt Rostock
Rostock, Germany
Immanuel Hospital Rüdersdorf
Rüdersdorf, Germany
Hospital Traunstein
Traunstein, Germany
Comprehensive Cancer Centre Main-Franken
Würzburg, Germany
MeSH Terms
Conditions
Study Officials
- STUDY CHAIR
Florian Lordick, Prof. Dr.
University of Leipzig
- STUDY CHAIR
Bend Alt-Epping, PD Dr.
University of Göttingen
- STUDY CHAIR
Anja Mehnert, Prof. Dr.
University of Leipzig
- STUDY CHAIR
Birgitt van Oorschot, Prof. Dr.
Comprehensive Cancer Centre Main-Franken, Würzburg
- STUDY CHAIR
Michael Thomas, Prof. Dr.
Heidelberg University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. Dr. med. (MD, PhD)
Study Record Dates
First Submitted
April 14, 2016
First Posted
April 26, 2016
Study Start
September 1, 2014
Primary Completion
October 1, 2019
Study Completion
October 1, 2019
Last Updated
March 7, 2019
Record last verified: 2019-03
Data Sharing
- IPD Sharing
- Will not share